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ABSTRACT  54 
 55 
Context: Familial isolated pituitary adenoma (FIPA) due to aryl hydrocarbon receptor interacting 56 
protein (AIP) gene mutations is an autosomal dominant disease with incomplete penetrance. Clinical 57 
screening of apparently unaffected AIP mutation (AIPmut) carriers could identify unapparent disease. 58 
Objective: To determine AIP mutational status of FIPA and young pituitary adenoma patients, 59 
analyzing their clinical characteristics, and to perform clinical screening of apparently unaffected 60 
AIPmut carrier family members. 61 
Design: Observational, longitudinal study, 2007-2013.  62 
Setting: International collaborative study, referral centers for pituitary diseases. 63 
Participants: FIPA families (n=216) and sporadic young-onset (d30 years) pituitary adenoma 64 
patients (n=404). 65 
Interventions: Genetic screening of patients for AIPmuts, clinical assessment of their family 66 
members and genetic screening for somatic GNAS1 mutations and the germline FGFR4 p.G388R 67 
variant. 68 
Main Outcome Measure(s): Clinical disease in mutation carriers, comparison of characteristics of 69 
AIPmut positive and negative patients, results of GNAS1 and FGFR4 analysis. 70 
Results: Thirty-seven FIPA families and 34 sporadic patients had AIPmuts. Patients with truncating 71 
AIPmuts had a younger age at disease onset and diagnosis, compared to patients with non-truncating 72 
AIPmuts. Somatic GNAS1 mutations were absent in tumors from AIPmut positive patients, and the 73 
studied FGFR4 variant did not modify the disease behavior or penetrance in AIPmut positive 74 
individuals. A total of 164 AIPmut positive unaffected family members were identified; pituitary 75 
disease was detected on 18 of those who underwent clinical screening.  76 
Conclusions: A quarter of the AIPmut carriers screened were diagnosed with pituitary disease, 77 
justifying this screening and suggesting a variable clinical course for AIPmut positive pituitary 78 
adenomas. 79 
4 
 
INTRODUCTION 80 
 81 
Familial isolated pituitary adenoma (FIPA) is characterized by the presence of pituitary adenomas in 82 
two or more members of the same family in the absence of other syndromic clinical features, such as 83 
those characteristic of multiple endocrine neoplasia type 1 (MEN1) and 4 (MEN4), Carney complex 84 
or tumors related to mutations in the succinate dehydrogenase (SDH) genes. FIPA is a heterogeneous 85 
condition, encompassing cases with unknown genetic cause and patients with mutations in the aryl-86 
hydrocarbon receptor interacting protein gene (AIP), with distinctive clinical characteristics. Germline 87 
AIP mutations (AIPmuts) play a role not only in a subset of FIPA families (1-4), but also in 88 
sporadically diagnosed pituitary adenomas (5-9), and in the setting of somatostatin analogue (SSA)-89 
resistant acromegaly (10). Another form of FIPA, X-linked acrogigantism (X-LAG), due to 90 
microduplications in the Xq26.3 region, has been recently identified in patients with very young-onset 91 
gigantism and pituitary adenoma/hyperplasia (11). 92 
 93 
The phenotype of AIPmut-associated pituitary adenomas has been described before (2-4;12), but a 94 
systematic follow-up of cases and families is lacking, due to the relative novelty of this pathogenic 95 
association (1), the variable disease penetrance (4;12-14) and the rarity of this clinical entity. We 96 
present the clinical and genetic characteristics of a large cohort of FIPA and simplex (patients with 97 
germline mutation and no family history) AIPmut positive patients, aiming:  (i) to perform a 98 
systematic follow-up of families to identify and characterize AIPmut positive carriers, (ii) to seek the 99 
role of disease-modifying genes on the variable phenotype and penetrance of the disease, and (iii) to 100 
confirm and extend the description of the phenotype of AIPmut positive patients, providing a 101 
comparison with AIPmut negative cases. We establish that genetic screening followed by clinical 102 
assessment identifies a large percentage of family members with pituitary abnormalities, supporting 103 
the facilitation of genetic diagnosis and follow-up of these patients and their families.  104 
 105 
PATIENTS AND METHODS 106 
 107 
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Our study population (1725 subjects, Table 1) was recruited via the collaborative research network of 108 
the International FIPA Consortium (15). Pituitary adenoma patients were grouped into 11 clinical 109 
diagnostic categories (Supplemental Table 1). The diagnoses of acromegaly, 110 
acromegaly/prolactinoma, gigantism, gigantism/ prolactinoma, and mild acromegaly (16) were 111 
grouped together under the category of ‘GH excess’ for some analyses.  112 
 113 
Between January 2007 and January 2014, we recruited patients from 35 countries from two different 114 
groups: either members of FIPA families, defined by the presence of pituitary adenomas in two or 115 
more members of a family without other associated clinical features (1-3;17) (‘familial’ cohort), or 116 
sporadically-diagnosed pituitary adenoma patients with disease onset at ≤30 years of age (‘sporadic’ 117 
cohort). As an exception to these inclusion criteria, one AIPmut positive >30 years sporadic patient 118 
was found thanks to AIP screening in the setting of a research study, and the screening of his relatives 119 
detected a second AIPmut positive pituitary adenoma case; this family was included in the familial 120 
cohort. The first patient reported in each FIPA family and all the sporadic patients were considered 121 
‘probands’. All the patients received treatment and were followed up in accordance with the 122 
guidelines and clinical criteria of their respective centers. Relevant clinical and family structure data 123 
were received from clinicians and/or patients, and genetic screening was performed in the families of 124 
all the AIPmut positive probands, selecting individuals according to their risk of inheriting the 125 
mutation, based on their position in the family tree, and extending the screening to as many 126 
generations as possible. In both familial and sporadic cases, other causes of familial pituitary 127 
adenomas, such as MEN1 and 4, Carney complex, pheochromocytoma/paraganglioma and pituitary 128 
adenoma syndrome and X-LAG were ruled out by clinical, biochemical and, in some cases, genetic 129 
tests, as appropriate. The study population included a great majority of new cases, but also previously 130 
diagnosed patients being followed-up by the participating centers and a few historical cases, 131 
corresponding to deceased members of FIPA families (further details in Supplemental Results). Four 132 
AIPmut positive patients (two with diagnosis of acromegaly and two with gigantism) died in the post-133 
recruitment period. Three of the deaths were due to cardiovascular causes (stroke, chronic heart 134 
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failure and acute coronary syndrome), while the exact cause of death is unknown in the fourth, a 135 
patient with long-standing untreated familial acromegaly.  136 
 137 
All the patients and family members included agreed to take part by providing signed informed 138 
consent forms approved by the local Ethics Committee. Further details on the study population and 139 
the procedures for genetic/clinical screening and search for disease-modifying genes are described in 140 
the Supplemental Material. 141 
 142 
Statistical analysis 143 
The qualitative, categorical variables were expressed as percentages and compared using the chi-144 
squared test or the Fisher’s exact test, as appropriate. The normal distribution of the quantitative 145 
variables was verified using the Shapiro-Wilk and the Kolmogorov-Smirnov tests for normality. 146 
Means and standard deviations were used to report parametric data, and non-parametric data were 147 
expressed as median and interquartile ranges. Parametric data were analyzed with the unpaired t-test, 148 
with a 95% confidence interval, while the Mann-Whitney U test was used for the non-parametric data. 149 
Statistical significance was considered when the P value was <0.05. All the statistical analyses were 150 
carried out using the GraphPad Prism 6 (GraphPad Software Inc.) and Stata 12 (StataCorp LP) 151 
statistical software. 152 
 153 
RESULTS 154 
 155 
Study population 156 
The familial cohort was composed of 216 FIPA families, including 156 new families (989 subjects: 157 
337 patients and 652 unaffected family members) and 60 previously described families (3;12), where 158 
46 new subjects (15 patients and 31 unaffected family members) were added to the previously 159 
reported 196 individuals (150 patients and 46 unaffected family members). The sporadic cohort 160 
originally included 409 pituitary adenoma patients ≤30 years old at disease onset, with no known 161 
familial history of pituitary adenoma, but we excluded five patients from further analysis due to 162 
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harboring an Xq26.3 microduplication. Of the remaining 404 sporadic patients, six were reported 163 
previously (3). In addition to the AIPmut screening, a subset of AIPmut negative FIPA (n=55) and 164 
sporadic (n=45) patients underwent genetic screening for other endocrine neoplasia-associated genes 165 
(Supplemental Table 2). All of these tests were negative for pathogenic variants. After the genetic 166 
screening and follow-up of the patients and carriers, 60 individuals in the familial cohort and seven in 167 
the sporadic cohort were classified as ‘not at risk’ of inheriting an AIPmut, and were excluded from 168 
further analysis. Twenty three individuals initially thought to be unaffected were identified with 169 
pituitary abnormalities (see details in the ‘Prospective diagnosis’ section). 170 
 171 
Genetic screening results 172 
Thirty-seven (17.1%) out of 216 FIPA families screened and 34 out of 404 sporadic patients (8.4%) 173 
were positive for pathogenic or likely pathogenic AIPmuts, accounting for a total of 71 AIPmut 174 
positive kindreds and 144 AIPmut positive patients (76.4% familial and 23.6% simplex, Table 2). We 175 
also identified 164 AIPmut positive apparently unaffected family members (see ‘Follow-up and 176 
prospective diagnosis’). Samples were not available from family members of 25 AIPmut positive 177 
simplex cases to establish the presence or lack of de novo mutations. We identified three pituitary 178 
adenoma patients (two with clinically non-functioning pituitary adenoma [NFPA] and one with a 179 
microprolactinoma) belonging to AIPmut positive FIPA families and being ‘at risk’ of inheriting, but 180 
not carrying an AIPmut; therefore they were considered as phenocopies.  181 
 182 
Thirty-one different AIPmuts (ten not previously reported) were identified in our study population: 12 183 
exclusively in familial cases, 12 in simplex cases only and seven in both settings (Table 3 and 184 
Supplemental Figure 1). Of the total mutations, 70.8% (22/31) predict a truncated or missing protein, 185 
and were termed as ‘truncating AIPmuts’ (Supplemental Figure 2). We also identified 11 apparently 186 
non-pathogenic AIP variants (three of them novel) in our population (Supplemental Table 3).  187 
 188 
A multiple regression analysis was performed to determine which clinical features could more 189 
accurately predict the likelihood of a patient to carry an AIPmut. An age at diagnosis ≥10 and <20 190 
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years conferred an odds ratio (OR) of 5.8 (P=0.000, 95% CI 3.1-10.8) of having an AIPmut, while the 191 
OR was 2.8 if the age at diagnosis was ≥20 and <30 years (P=0.000, 95% CI 1.3- 5.7); thus, an age at 192 
diagnosis between 10 and 30 years is the best predictor of AIPmuts. Inversely, a diagnosis of 193 
prolactinoma resulted in an OR of 0.2 (P=0.000, 95% CI 0.1-0.5).  194 
 195 
Genotype-phenotype correlation within the AIPmut positive cohort 196 
Truncating mutations accounted for 78.9% (15/19) of the AIPmuts found in the familial cohort, and 197 
for 57.9% (11/19) of those detected in the sporadic cohort. To study a possible difference in disease 198 
penetrance between truncating and non-truncating mutations, we compared the number of affected 199 
individuals with truncating AIPmuts in the familial (85/110 [77.3%]) and simplex cohorts (21/34 200 
[61.8%]), finding no significant difference, although a trend was observed (P=0.0729, analysis 201 
included prospectively diagnosed patients). No significant differences were found regarding the 202 
proportion of GH excess cases, number of patients per family, maximum tumoral diameter, frequency 203 
of macroadenomas, extrasellar invasion or number of treatments received between the patients with 204 
truncating and non-truncating mutations. However, patients with truncating mutations were 205 
significantly younger at disease onset (median 16 [IQR 15-25] vs. 22 [IQR 17.3-27.8] years, 206 
P=0.0046, Figure 1a) and at diagnosis (median 21 [IQR 16-30] vs. 27 [IQR 20.8-37] years, 207 
P=0.0028, Figure 1b), and the occurrence of pediatric cases was more common in this group (60% 208 
[57/95], Figure 1c), compared to the patients with non-truncating AIPmuts (33.3% [12/36], 209 
P=0.0064). In concordance with these differences, gigantism accounted for a significantly higher 210 
proportion of the GH excess cases in the patients with truncating AIPmuts (54.7% [47/86]), compared 211 
to those with non-truncating AIPmuts (30% [9/30], P=0.0200). As p.R304* was the most common 212 
AIPmut in our study population (20 kindreds), we analyzed if these patients behaved differently to 213 
other patients with truncating mutations, finding more affected individuals per family (median 4 [IQR 214 
2.5-5]), compared to families with other AIPmuts (median 2 [IQR 2-3], P=0.0133). When considering 215 
all the AIPmut positive patients together (familial and sporadic), we found a higher proportion of 216 
pediatric patients among those with the AIP p.R304* mutation (65.8% [25/38] vs. 46.5% [40/86], 217 
P=0.0475).  218 
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 219 
Clinical and histopathological features 220 
Findings regarding gender distribution, age at onset/diagnosis, distribution of clinical diagnoses, 221 
tumor size/extension, pituitary apoplexy, histopathological features, extrapituitary tumors and specific 222 
analyses of patients with GH excess and with gigantism are detailed in the Supplemental Material. 223 
 224 
Disease penetrance 225 
To calculate the penetrance of pituitary adenomas among AIPmut positive families, complete data is 226 
needed both for phenotype and genotype. Therefore, we have selected three families (two with 227 
p.R304*, and one with p.A34_K39del mutations) where complete data was available in three or more 228 
generations for consenting ‘at risk’ individuals. The AIP genotype was known in 76.6% (range 68.4-229 
94.7%) of the individuals at risk; of them, 16.8% were patients and 83.2% were unaffected carriers. 230 
The gender distribution was similar between patients and unaffected carriers. The mean penetrance in 231 
these three families was 28.6% (19-38.1), and it decreased to 22.7% (18.2-26.7) when 50% of the 232 
individuals at risk with unknown genotype were considered as unaffected carriers. When the 233 
prospectively diagnosed patients were omitted from this calculation, the total penetrance of pituitary 234 
adenomas was 12.5%, highlighting the importance of the follow-up of apparently unaffected carriers 235 
for the correct calculation of the disease penetrance. 236 
 237 
As penetrance cannot be appropriately calculated for AIPmut negative families, we assessed the 238 
number of affected family members. The AIPmut positive families had more affected individuals per 239 
family than the AIPmut negative families (P<0.0001, Supplemental Figure 7e). While 84.9% 240 
(152/179) of the AIPmut negative families had only two affected members, 48.6% (18/37) of the 241 
AIPmut positive families had three or more pituitary adenoma patients per family. The maximum 242 
number of affected individuals within the same family was eight (six of them prospectively 243 
diagnosed) in a family carrying the p.R304* AIPmut, and the maximum number of cases of gigantism 244 
in the same family was five, in a FIPA family with the p.E24* AIPmut. 245 
 246 
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Follow-up and prospective diagnosis 247 
Out of the 164 originally identified AIPmut carriers, 160 were available and advised to undergo 248 
biochemical and clinical screening. Prospective diagnosis of a pituitary adenoma was established in 249 
11.3% (18 subjects, 11 males) of the individuals originally considered as unaffected AIPmut carriers.  250 
 251 
Six of the prospectively diagnosed patients had acromegaly (one of them with PRL co-secretion), one 252 
patient had gigantism, two patients were diagnosed with mild acromegaly (16) and nine patients 253 
harbored NFPAs.  Out of the 142 individuals remaining as apparently unaffected AIPmut carriers, 79 254 
(55.6%) underwent clinical assessment and one or more biochemical or imaging tests, while 63 255 
subjects (44.4%) had only clinical evaluation. 256 
 257 
The prospective cases were diagnosed at an older age than the rest of the patients (median 30 [IQR 258 
22.8-39.5] vs. 23 [IQR 16-33] years, P=0.025). At diagnosis, seven of the prospectively diagnosed 259 
patients were symptomatic (headaches, arthralgias, acral growth, facial changes, weight gain or 260 
hyperhidrosis). Five of the 18 prospectively diagnosed tumors were macroadenomas, in contrast with 261 
a predominance of macroadenomas (89.9%, 71/79) in the rest of the AIPmut positive FIPA patients 262 
(P<0.0001). The maximum diameter was significantly smaller for prospective cases (median 5.8 [IQR 263 
4.7-14.4] vs. 16.5 [IQR 10-29], P=0.0002). Four of the patients with macroadenomas had surgery and 264 
the histopathological study confirmed GH or GH/PRL positive adenomas. The fifth macroadenoma 265 
was identified in a 68-year-old male patient with well controlled hypertension and diabetes mellitus 266 
and no other comorbidities or symptoms, who did not wish to receive any treatment. In addition, one 267 
AIPmut negative pituitary adenoma patient, harboring a 25mm NFPA, was prospectively diagnosed as 268 
part of an AIPmut positive family (brother of the AIPmut positive proband).  269 
 270 
Further seven subjects had abnormalities in their screening tests, but a pituitary disease was not 271 
confirmed: five individuals had slightly elevated IGF-1 levels for their age/gender, one patient 272 
displayed acromegaloid features but normal pituitary MRI and biochemistry, and a 17-year-old female 273 
had repeatedly borderline high IGF-1 and incompletely suppressed GH on OGTT, but her bulky 274 
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pituitary gland (11mm in height), normal at this age group, is not changing during follow-up and her 275 
biochemical results are now within the normal range, after three years of follow-up.  276 
 277 
The global penetrance of pituitary adenomas among the individuals initially considered as unaffected 278 
AIPmut carriers was 11.3% (18/160). However, the penetrance was higher in the group of carriers 279 
who underwent biochemical and imaging investigations, varying between 18.6 and 28.1% depending 280 
on the depth of screening (Figure 2). Overall, these data suggest that approximately 20-25% of the 281 
apparently unaffected AIPmut carriers screened with biochemical or imaging tests will be identified 282 
with a pituitary adenoma at some point in their lives. 283 
 284 
Clinical screening was not systematically performed in the AIPmut negative FIPA unaffected family 285 
members. Nevertheless, due to the increased disease awareness given by the existence of previous 286 
pituitary adenoma cases within their families, four individuals (three females and one male) from 287 
three different AIPmut negative FIPA families were prospectively diagnosed. Three of them harbored 288 
NFPAs, but we lack complete information about the fourth patient. The mean age at diagnosis in the 289 
three NFPA cases was 37 years, and only one patient referred symptoms at diagnosis (galactorrhea, 290 
not clearly associated to stalk compression, and lethargy). All of them had microadenomas, with a 291 
mean diameter of 6.5mm, and did not require any therapeutic intervention other than hormonal 292 
replacement in one case.  The characteristics of these cases resemble those of incidentalomas; 293 
however, the occurrence of two prospective cases in the same family supports an apparent inherited 294 
component.  295 
 296 
Disease-modifying genes 297 
We have studied the role of two possible disease-modifying genes: GNAS1 (18) (somatic) and FGFR4 298 
(germline) (19). GNAS1 mutations were absent in all the studied AIPmut positive somatotropinomas 299 
(n=23), but were detected in 50% of the AIPmut negative familial somatotropinomas (5/10), 16.7% of 300 
the AIPmut negative young-onset cases (1/6), and 26.3% of the unselected acromegaly cases studied 301 
(5/19). The distribution of the FGFR4 p.G388R SNP conserved the Hardy-Weinberg equilibrium (20) 302 
12 
 
and the genotype distribution was similar between patients (n=98) and carriers (n=108) (P=0.523). 303 
The age at onset and at diagnosis, tumor size and frequency of extrasellar invasion were not 304 
significantly different between the GG (wild-type) and GR/RR patients.  305 
 306 
DISCUSSION 307 
 308 
AIPmuts are prevalent in young onset GH-excess patients (24%) and FIPA (17.1%), with more than 309 
double frequency in patients with gigantism (46.7%) in our cohort, in concordance with other studies 310 
(7;9;21;22). However, in contrast to previous reports, in this large and extensively studied cohort there 311 
was no predominance of male patients among the AIPmut positive familial cases, and equal numbers 312 
of male and female unaffected carriers were identified. Earlier studies (3;4;12;23) may have had an 313 
ascertainment bias for families with cases of gigantism, a disease that is more prevalent in males, at 314 
least partly due to the physiologically later puberty and therefore later cessation of growth in boys.  315 
 316 
We have demonstrated that around a quarter of the individuals initially identified as unaffected 317 
AIPmut carriers who underwent clinical screening tests were diagnosed with pituitary abnormalities. 318 
Full clinical screening identified 28.1% of the carriers, with fewer tests understandably resulting in 319 
fewer positive cases. Our data suggest that not all the AIPmut-associated pituitary adenomas have a 320 
rapidly growing, aggressive phenotype. The follow-up of these patients allowed us to observe some 321 
probably very early cases of acromegaly, where the current clinical scenario had not indicated 322 
intervention at data closure. We cannot rule out that some of the small NFPAs are indeed 323 
incidentalomas, similar to those frequently observed in AIPmut negative subjects of the general 324 
population. 325 
 326 
This frequency of prospective diagnosis may justify the clinical screening and, possibly, follow-up of 327 
all the AIPmut positive unaffected carriers. Our data would support the assessment of all the newly 328 
identified AIPmut carriers (clinical examination/history, PRL and IGF-1, as a minimum, up to a full 329 
screening, including also an OGTT and contrast-enhanced pituitary MRI). Follow-up of the younger 330 
13 
 
family members should continue until at least the 30 years of age, preferably annually, with clinical 331 
assessment and basal pituitary hormonal levels, leaving stimulation tests for cases with suspicion of 332 
pituitary disease and a follow-up MRI if necessary (24;25). The cost-effectiveness and the possible 333 
psychological burden of this approach will need future study. Stopping the follow-up should be 334 
considered in older patients, given the low possibility of detecting new pituitary adenoma patients in 335 
these individuals after the fifth decade of life (24;25). Once a case has been prospectively diagnosed, 336 
the treatment and follow-up should proceed as for the general population of pituitary adenoma 337 
patients, as there are no data to suggest a different type of treatment in AIPmut positive patients (26).  338 
 339 
The genetic and clinical screening of AIPmut negative FIPA families is uncertain at this point. 340 
Baseline screening and follow-up of obligate carriers could be considered, keeping in mind that the 341 
age of onset is considerably older in these families. Education on possible signs and symptoms of 342 
family members is a viable option in the routine setting. Patients with GH excess starting before the 343 
age of five should be tested for the recently identified Xq26.3 chromosomal microduplications (11). 344 
We expect that the identification of further genes implicated in the pathogenesis of FIPA in the next 345 
years will allow us to tailor these recommendations in accordance with the clinical behavior of each 346 
genetic entity.  347 
 348 
The genetic screening of sporadic young-onset pituitary adenoma patients with no evidence of other 349 
endocrine tumors should be focused on AIPmuts in first instance in cases of GH excess (with or 350 
without PRL co-secretion) and on MEN1 mutations in cases of  prolactinoma (9), as this can be the 351 
first manifestation of MEN1 (27). Whether it would be advisable to continue screening young patients 352 
with other diagnoses for AIPmuts out of the setting of research studies needs longer follow-up.  353 
 354 
To explain the variable clinical phenotype in our AIPmut positive patients, we evaluated the possible 355 
influence of two disease-modifying genes, GNAS1 and FGFR4. While somatic GNAS1 mutations are 356 
common in unselected somatotropinomas (4.4-59% of the cases) (28-35), we have not identified any 357 
in adenomas from AIPmut positive patients, suggesting that germline AIPmuts and somatic GNAS1 358 
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mutations are mutually exclusive in somatotropinomas. GNAS1 mutations have rarely been studied in 359 
pediatric patients with acromegaly and gigantism, and they seem to be an extremely infrequent 360 
finding in this age-group (36;37). A recent study has shown no change in the AIP immunostaining in 361 
sporadic somatotropinomas in the presence of GNAS1 mutations (38). The characteristic phenotype of 362 
adenomas containing the GNAS1 mutations (small (32;39), highly responsive to the treatment with 363 
SSAs, and more often densely granulated according to some (40), but not all studies (41)), seems to 364 
be in contrast with the typical AIPmut positive tumor phenotype. On the other hand, in somatotroph 365 
adenomas of AIPmut negative FIPA patients, half of the tested samples had GNAS1 mutations. This 366 
suggests that in AIPmut negative FIPA, somatic GNAS1 mutations could exist in a similar frequency 367 
as to in unselected somatotropinomas and possibly, in addition to a germline predisposing mutation, 368 
may play a role in their pathogenesis.  369 
 370 
The FGFR4 gene SNP rs351855 (c.1162G>A, p.G388R), with a minor allele frequency of 0.3, is a 371 
predictor of progression and poor prognosis in a variety of human neoplasms (42). A role for 372 
rs351855 as a facilitator of somatotroph cell tumorigenesis has been recently proposed (19), and we 373 
hypothesized that this variant could increase the penetrance and/or size and extension of AIPmut 374 
positive pituitary adenomas. The screening for this SNP in our AIPmut positive patients failed to 375 
show increase in size, extension or apoplexy, even though this association had previously been 376 
suggested in sporadic acromegaly patients (19), and no earlier onset or higher penetrance were 377 
observed. The lack of association with these two potentially disease-modifying genes suggests that 378 
AIPmut-related pituitary adenomas are regulated by different pathogenic mechanisms than unselected 379 
somatotropinomas. 380 
 381 
We recognize the numerous limitations of our study. We chose an arbitrary age cut-off (≤ 30 years), 382 
in concordance with previous AIP-related publications, but our data shows that only 13.2% of the 383 
AIPmut positive patients had disease onset after the age of 30 years. Our patients were recruited from 384 
different genetic backgrounds and this could have influenced the disease penetrance and presentation. 385 
On the other hand, 19.7% of the AIPmut positive kindreds (24.3% of the AIPmut positive patients) 386 
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belong to a cohort with a founder AIPmut (p.R304*), originally from Northern Ireland (14). The 387 
larger number of subjects screened in these families provided a higher number of carriers and chance 388 
for detection of affected individuals. Additional genetic traits possibly co-segregating with this 389 
founder mutation could modify the phenotype and thus introduce a bias into our results. Full genotype 390 
and phenotype data were not available for all the families; therefore, we limited our penetrance 391 
calculations to three large, well-characterized families. A better assessment of the prevalence of 392 
pituitary apoplexy and extrapituitary adenomas in AIPmut positive patients would require a large 393 
control group, screened ad hoc, which was beyond the scope of this study. Finally, the data about 394 
therapeutic modalities was limited, hampering the analysis of the response to different treatments.   395 
 396 
CONCLUSIONS 397 
 398 
The analysis of this large cohort of FIPA patients allowed us establishing a number of novel aspects 399 
of FIPA. A phenotype-genotype correlation was found with younger onset of disease in patients with 400 
truncating AIPmuts. We identified a surprisingly high percentage of somatic GNAS1 mutations in the 401 
AIPmut negative somatotropinomas, and their absence in AIPmut positive tumors. The lack of 402 
influence of the germline FGFR4 p.G388R variant on disease penetrance/severity suggests that 403 
currently unknown factors drive penetrance and variable phenotype in AIPmut positive pituitary 404 
adenomas. The presence of milder, more indolent disease in some AIPmut positive subjects has been 405 
established. Genetic and clinical screening leads to the prospective identification of an unexpectedly 406 
high proportion of affected patients in the originally apparently unaffected carrier group, resulting in 407 
earlier diagnosis and treatment and, possibly, better long-term outcome (25). The recruitment of a 408 
large study population with this uncommon disease has only been possible thanks to world-wide 409 
collaboration. 410 
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FIGURE LEGENDS 
 
Figure 1. Patients with truncating vs. non-truncating AIPmuts. a) Patients with truncating 
AIPmuts present with a more aggressive phenotype, characterized by an earlier age at onset 
(P=0.005) and b) at diagnosis (P=0.003). c) This earlier disease onset results in a higher frequency of 
pediatric cases (n [total]= 131); in fact, the majority of the patients with truncating mutations present 
in childhood and adolescence. **, P<0.01.   
 
Figure 2. Penetrance in screened AIPmut positive carriers (n [total]=160). The probability of 
detecting new cases of pituitary adenomas within apparently unaffected AIPmut carriers depends on 
the clinical assessment and the type of complementary biochemical/imaging studies included in the 
screening protocol (see text). 
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Table 1. Study population: demographics and general description 
 Familial cohort Sporadic cohort Combined 
Total individuals, no. (%) 1231 (71.4) 494 (28.6) 1725 (100) 
Females, no. (%) 668 (54.3) 250 (50.6) 918 (53.2) 
Current age, median 
(range, [IQR]) 
46.2 (2-97 [32-62]) 35 (3-77 [26-42]) 42.6 (2-97 [29-56]) 
Clinical status, no. (%):    
Affected 502 (40.8) 404 (81.8) 906 (52.5) 
Unaffected 729 (59.2) 90 (18.2) 819 (47.5) 
Affected males, no. (%) 219 (43.6) 203 (50.2) 422 (46.6) 
Affected females, no. (%) 283 (56.4) 201 (49.8) 484 (53.4) 
Diagnoses, no. (%):    
Acromegaly 170 (33.9) 203 (50.2) 373 (41.2) 
Acromegaly/prolactin
oma 
17 (3.4) 12 (3) 29 (3.2) 
Cushing's disease 24 (4.8) 21 (5.2) 45 (5) 
FSHoma 2 (0.4) 1 (0.2) 3 (0.3) 
Gigantism  44 (8.8) 65 (16.1) 109 (12) 
Gigantism/prolactino
ma 1 (0.2) 10 (2.5) 11 (1.2) 
Mild acromegaly 2 (0.4) - 2 (0.2) 
NFPA 91 (18.1) 21 (5.2) 112 (12.4) 
Pituitary tumor 17 (3.4) 2 (0.5) 19 (2.1) 
Prolactinoma 134 (26.7) 67 (16.6) 201 (22.2) 
TSHoma - 2 (0.5) 2 (0.2) 
GH excess patients, no. 
(%) 
234 (46.6) 290 (71.8) 524 (57.8) 
IQR: interquartile range. FSHoma: FSH secreting adenoma. TSHoma: thyrotropinoma. 
NFPA: non-functioning pituitary adenoma.  
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Table 2. Screening for AIP mutations 
  Familial cohort Sporadic cohort Combined 
  
AIPmut positive 
familial 
AIPmut 
negative 
familial 
Total familial AIPmut positive simplex 
AIPmut 
negative 
sporadic 
Total sporadic 
AIPmut positive 
familial and 
simplex 
AIPmut 
negative 
familial and 
sporadic 
Total 
Total number of kindreds, no. (%): 
37 (17.1% of 
familial) 
179 (82.9% of 
familial) 
216  
(34.8% of total) 
34 (8.4% of 
sporadic) 
370 (91.6% of 
sporadic) 
404  
(65.2% of total) 
71  
(11.5% of total) 
549  
(88.5% of total) 
620 (100) 
Total individuals, no. (%): 
475 (38.6% of 
familial) 
756 (61.4% of 
familial) 
1231  
(71.4% of total) 
82 (16.6% of 
sporadic) 
412 (83.4% of 
sporadic) 
494  
(28.6% of total) 
557  
(32.3% of total) 
1168  
(67.7% of total) 
1725 (100) 
Genetic status, no. (%):          
AIPmut negative patients 3 (0.6) 389 (51.5)* 392 (31.8) - 370 (89.8) 370 (74.9) 3 (0.5) 759 (65) 762 (44.2) 
AIPmut positive tested patients  95 (20) - 95 (7.7) 34 (41.5) - 34 (6.9) 129 (23.2) - 129 (7.5) 
At risk, but not tested 33 (6.9) - 33 (2.7) 8 (9.8) - 8 (1.6) 41 (7.4) - 41 (2.4) 
Not at risk 48 (10.1) 12 (1.6) 60 (4.9) 7 (8.5) - 7 (1.4) 55 (9.9) 12 (1) 67 (3.9) 
Obligate unaffected carriers, not 
tested 8 (1.7) - 8 (0.6) 2 (2.4) - 2 (0.4) 10 (1.8) - 10 (0.6) 
Predicted AIPmut positive patients 15 (3.2) - 15 (1.2) - - - 15 (2.7) - 15 (0.9) 
Unaffected AIPmut tested carriers 120 (25.3) - 120 (9.7) 16 (19.5) - 16 (3.2) 136 (24.4) - 136 (7.9) 
Unaffected and AIPmut negative 153 (32.2) - 153 (12.4) 15 (18.3) - 15 (3) 168 (30.2) - 168 (9.7) 
Unaffected relatives of AIPmut 
negative patients - 355 (47) 355 (28.8) - 42 (10.2) 42 (8.5) - 397 (34) 397 (23) 
Summary of AIPmut positive 
individuals, no. (%):          
Total AIPmut positive patients:† 110 (23.2) - 110 (8.9) 34 (41.5) - 34 (6.9) 144 (25.9) - 144 (8.3) 
Total unaffected AIPmut carriers:‡ 128 (26.9) - 128 (10.4) 18 (22) - 18 (3.6) 146 (26.2) - 146 (8.5) 
* In AIPmut negative FIPA families, 199 patients were tested for AIPmuts, the rest (n=190) were assumed to be negative.                                                                                                                                 
 †This is equal to the sum of tested AIPmut positive patients plus the predicted AIPmut positive patients.                                                                                                                                                              
‡ Sum of tested unaffected carriers plus obligate unaffected carriers. 
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Table 3. AIP pathogenic or likely pathogenic mutations in the familial and sporadic cohorts 1 
Mutation 
(DNA level  
[protein level]) 
Mutation type Pathogenic Location in protein 
Familial 
cohort 
(n=238)* 
Simplex 
cohort 
(n=52)* 
Combined 
(n=290)* 
References/ 
SR‡ 
g.4856_4857CG>AA Promoter Yes† Not in protein           (5' UTR) 3 (1.3) - 3 (1) (3;12)/(SR30)  
c.3G>A (p.?) Start codon Likely† N-terminus 2 (0.8) - 2 (0.7) This paper 
c.40C>T (p.Q14*) Nonsense Yes† N-terminus 2 (0.8) - 2 (0.7) (1)/(SR31;32)  
c.70G>T (p.E24*) Nonsense Yes† N-terminus 9 (3.8) - 9 (3.1) (3)/(SR33)  
c.74_81delins7 
(p.L25Pfs*130) Frameshift Yes† PPIase domain 10 (4.2) - 10 (3.4) (12)/(SR34)  
c.100-1025_279+357del 
(ex2del) (p.A34_K93del) 
Large genomic 
deletion Yes† PPIase domain 12 (5) 2 (4) 14 (4.8) (SR35)  
c.100-18C>T  Intronic Likely Not in protein (intron 1) - 3 (6) 3 (1) (3;7;10)/(SR31)  
c.241C>T (p.R81*) Nonsense Yes† PPIase domain 12 (5) 4 (8) 16 (5.5) (3)/(SR30;36-38)  
c.249G>T (p.G83Afs*15) 
Splice site 
(cryptic splice 
site) 
Yes† PPIase domain 4 (1.7) - 4 (1.4) (12) 
c.338_341dup 
(p.L115Pfs*16) Frameshift Yes† PPIase domain - 2 (4) 2 (0.7) (6) 
c.427C>T (p.Q143*) Nonsense Yes† 
Between 
PPIase and 
TPR1 domains 
- 1 (2) 1 (0.3) This paper 
c.469-2A>G 
(p.E158_Q184del) Splice site Likely TPR1 domain - 1 (2) 1 (0.3) (5)/(SR39;40)  
c.490C>T (p.Q164*) Nonsense Yes† 
Between 
PPIase and 
TPR1 domains 
3 (1.3) - 3 (1) (12) 
c.570C>G (p.Y190*) Nonsense Yes† TPR1 domain 9 (3.8) - 9 (3.1) This paper 
c.662dupC (p.E222*) Nonsense Yes† Between TPR1 and 2 domains 3 (1.3) - 3 (1) (12) 
c.713G>A (p.C238Y) Missense Yes TPR2 domain 4 (1.7) - 4 (1.4) (3)/(SR33)  
c.783C>G (p.Y261*) Nonsense Yes† TPR2 domain 4 (1.7) - 4 (1.4) (9)/(SR39;41;42)  
c.787+9C>T Intronic Uncertain Not in protein    (intron 5) - 1 (2) 1 (0.3) This paper 
c.804C>A (p.Y268*) Nonsense Yes† TPR3 domain 19 (8) 3 (6) 22 (7.6) (SR43;44)  
c.805_825dup 
(p.F269_H275dup) 
In-frame 
insertion Yes TPR3 domain 16 (6.7) 2 (4) 18 (6.2) (3)/(SR30;39;45)  
c.807C>T (p.(=)) 
Splice site 
(reduced 
transcript level) 
Yes TPR3 domain 7 (2.9) 4 (8) 11 (3.8) (3;5;7;10;12)/ (SR46;47)  
c.811C>T (p.R271W) Missense Yes TPR3 domain - 1 (2) 1 (0.3) (2;7;12)/(SR48)  
c.816delC (p.K273Rfs*30) Frameshift Yes† TPR3 domain - 1 (2) 1 (0.3) This paper 
c.868A>T (p.K290*) Nonsense Yes† TPR3 domain - 1 (2) 1 (0.3) This paper 
c.872_877delTGCTGG 
(p.V291_L292del) 
In-frame 
deletion Yes TPR3 domain - 1 (2) 1 (0.3) This paper 
c.910C>T (p.R304*) Nonsense Yes† C-terminal α-helix 88 (37) 16 (31) 104 (35.9) 
(1-3;5;7;9;12;14)/ 
(SR39;49-51)  
c.911G>A (p.R304Q) Missense Yes C-terminal α-helix 20 (8.4) 3 (6) 23 (7.9) 
(3;5;7;9;12)/ 
(SR31;39;52;53)  
c.967delC (p.R323Gfs*39) Frameshift Yes† C-terminal α-helix - 4 (8) 4 (1.4) This paper 
c.976_977insC 
(p.G326Afs*?) Frameshift Yes† 
C-terminal α-
helix - 1 (2) 1 (0.3) This paper 
c.978dupG (p.I327Dfs*?) Frameshift Yes† C-terminal α-helix - 1 (2) 1 (0.3) This paper 
c.1-?_993+?del- (whole 
gene deletion) 
Large genomic 
deletion Yes† 
Absence of the 
whole protein 11 (4.6) - 11 (3.8) (12) 
* Number of positive individuals for each mutation, considering the AIPmut positive tested individuals, the obligate carriers and the 
predicted AIPmut patients.  
† Truncating mutation. ‡ Supplemental references (see Supplemental Material). 
PPIase, peptidylprolyl isomerase. TPR, tetratricopeptide repeat. 
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SUPPLEMENTAL MATERIAL 
 
SUPPLEMENTAL METHODS 
Study population 
At recruitment, relevant clinical and biochemical data were collected at each participating center 
using a standard datasheet designed for this study (available on request) and all the information was 
entered into our central database. Data about the follow-up, treatments and current status of the 
patients were prospectively requested and collected from the collaborating centers and directly from 
the patients. Data about the historical cases were collected from family members and from hospital 
archives, when available. With a few exceptions, genetic screening results were directly sent to our 
center and entered in the database. The available data did not allow a comprehensive analysis of the 
response to specific therapeutic modalities.    
 
We identified subjects ‘at risk’ (those with the possibility of inheriting an AIPmut), ‘obligate carriers’ 
(based on their position in family tree, AIPmuts were verified when possible) and ‘unaffected 
carriers’. Therefore, in our analysis the term ‘unaffected carrier’ includes all the relatives of AIPmut-
positive patients without clinical manifestations of a pituitary adenoma and with either a genetic 
screening positive for the AIPmut present in the proband or with a position in the family tree defining 
them as ‘obligate carriers’. Additionally, the analysis of the family trees led to the identification of 
some affected individuals as ‘predicted AIPmut-positive patients’, defined as individuals with an 
established clinical diagnosis of pituitary adenoma in whom the genetic screening could not be carried 
out due to unavailability of a DNA sample, but in whom the presence of the mutation was assumed 
based on both the phenotype and the position in the family tree. Therefore, the term ‘AIPmut-positive 
patient’ will refer to both ‘predicted AIPmut-positive patients’ and ‘AIPmut-positive patients’ in 
whom the presence of the mutation was verified. Subjects ‘not at risk’ of inheriting an AIPmut were 
defined based on their position in the family tree. In the sporadic cohort, the AIPmut-positive patients 
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with no apparent familial history of pituitary disease were also referred as ‘simplex’ cases as they can 
be considered the first case of a potentially hereditary disease.  
 
Genetic and clinical screening 
Pituitary adenoma patients and their apparently unaffected relatives were screened for AIPmuts using 
Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA), as described in 
Supplemental Material. We have divided the AIP variants into five classes according to the likelihood 
of pathogenicity, as recommended by Plon et al. (SR1): definitely pathogenic, likely pathogenic, 
uncertain, unlikely pathogenic and not pathogenic. All the unaffected individuals with positive genetic 
screening for AIPmuts were advised to undergo clinical, biochemical and image screening tests for the 
early diagnosis of possible pituitary disease, on an annual basis or as appropriate. The 
recommendations for screening were based on the published experience of our group (24) and others 
(26). Additional genetic tests were performed in subjects with no pituitary adenomas, but with other 
clinical features indicative of such tests (screening for mutations in BRCA1 and 2 and TP53 was 
performed in members of a family with breast cancer, osteosarcoma and a neuroendocrine tumor of 
the colon), as well as and in a randomly selected cohort of AIPmut-negative FIPA probands, searching 
for mutations in other genes via direct sequencing and MLPA (BRCA1 and 2, CDKN1B, MEN1, 
TP53, PRKAR1A) or via a next-generation sequencing panel (MAX, RET, SDHA, SDHAF2, SDHB, 
SDHC, SDHD, TMEM127, and VHL) (SR2).  
 
Genomic DNA was obtained from blood (Ilustra DNA Extraction Kit BACC2, GE Healthcare, Little 
Chalfont, UK) or saliva (Oragene-DNA [collection] and prepIT-L2P [extraction] kits, DNA Genotek, 
Ontario, Canada) samples. The detection of the AIP gene variants and dosage was performed at the 
Molecular Genetics Laboratory, Royal Devon and Exeter, NHS Foundation Trust for the great 
majority of the samples, as previously described (3;12). Although the genetic tests were performed in 
one of the largest Genetics laboratories in the world, with appropriate quality controls, we cannot rule 
out that mutations were not identified in a small number of cases, due to either technical problems or 
due to location of mutations in areas not analyzed (such as intronic regions). The pathogenicity of the 
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detected variants was assessed using the Pathogenic Or Not-Pipeline (PON-P) and Alamut 2.2.1 in 
silico prediction programs, as well as considering the scientific literature concerning clinical and 
experimental data on the previously reported variants. Only those variants considered as definitely or 
likely pathogenic (SR1) were included in the study. Additionally, we included one novel intronic 
variant with no experimental data available, for which the prediction software could not exclude 
pathogenicity. The variants described in this paper are listed by their position in the DNA, with the 
corresponding change at the protein level in parentheses, according to the nomenclature guidelines of 
the Human Genome Variation Society (HGVS) version 1.0 (SR3) and the changes proposed for the 
version 2.0 (http://www.hgvs.org/mutnomen/). The nomenclature was verified using the Mutalyzer 
2.0.beta-21 software (http://www.lovd.nl/mutalyzer/). The positions in the DNA are based on the 
GRCh37/hg19 assembly of the human genome and the human AIP reference sequence (Locus 
Reference Genomic code LRG_460 (SR4), based on NG_008969.1 and NM_003977.2). Array 
comparative genomic hybridization analysis was performed in a group of patients with gigantism, and 
patients positive for Xq26 microduplications (11) were excluded from further analysis.  
 
Disease-modifying genes 
Genomic DNA (gDNA) samples from 98 AIPmut-positive patients (55 males/43 females) and 108 
unaffected AIPmut carriers (56 males/52 females) were subjected to PCR, using previously described 
primers (SR5) and screened for the FGFR4 p.G388R (rs351855) single nucleotide polymorphism 
(SNP). Additionally, gDNA was extracted from paraffin-embedded somatotropinomas for 23 AIPmut-
positive patients (familial and simplex), ten AIPmut-negative FIPA patients and six AIPmut-negative 
sporadic patients and cDNA was obtained from 19 frozen somatotropinomas from unselected 
acromegaly cases (control group, 13 males and six females, age at diagnosis 37-77 years).  All these 
samples were screened for mutations in the GNAS1 codons 201 and 227 using previously described 
primers for gDNA (SR6), and the primers  5’-CAAGCAGGCTGACTATGTGC-3’ and 5’-
ACCACGAAGATGATGGCAGT-3’ for cDNA. The sequence analysis of the FGFR4 and GNAS1 
PCR products was carried out by Sanger sequencing (BigDye Terminator v 3.1 kit in and ABI 3730 
capillary sequencer, Applied Biosystems, Foster City, CA, USA).   
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SUPPLEMENTAL RESULTS AND DISCUSSION 
 
Clinical and histopathological features 
Gender distribution  
Among the familial patients, there was a significantly different gender distribution of the affected 
individuals between the AIPmut-positive and negative subgroups (P=0.0015, Supplemental Figure 
3a), showing a predominance of females in the AIPmut-negative families. This difference is unlikely 
to be due to a selection bias, as the gender distribution was not significantly different between affected 
and unaffected individuals in the whole study population (P=0.8581), or, in the familial cohort, 
between unaffected AIPmut-positive and negative individuals (P=0.4421, Supplemental Figure 3b), 
or between AIPmut-positive affected and unaffected individuals (P=0.1367). We did not see a 
difference in gender distribution between the AIPmut-positive and negative sporadic patients either 
(P=0.1605, Supplemental Figure 3c). 
 
Age 
Familial patients 
FIPA AIPmut-positive patients were younger at disease onset (Supplemental Figure 4a) compared 
with AIPmut-negative FIPA patients. In the AIPmut-positive subgroup, the earliest age at onset was 
three years, while in the AIPmut-negative families a female patient with Cushing’s disease had the 
earliest disease onset at seven years. Most of the AIPmut-positive FIPA patients (71.7% [71/99]) 
developed their pituitary adenomas during the second and third decades of life (10-29 years), whereas 
only 39.2% (121/309) of the AIPmut-negative FIPA patients had their first signs/symptoms of 
pituitary adenoma during the same stage of life (P<0.0001, Supplemental Figure 4a and b). The age at 
diagnosis was also significantly different (P<0.0001): 68.2% (75/110) of the AIPmut-positive FIPA 
patients were diagnosed at ≤30 years of age, whereas the diagnosis was established in only 36.7% 
(116/316) of the AIPmut-negative patients by that age. The earlier disease presentation was also 
reflected in a much higher frequency of pediatric cases (disease onset at ≤18 years of age, 
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Supplemental Figure 4c) in the AIPmut-positive FIPA families, compared with the AIPmut-negative 
FIPA families (44.1 vs. 11.8%, P<0.0001). These distributions were calculated taking into 
consideration the prospectively diagnosed AIPmut-positive patients; however, the statistical analysis 
results were not significantly different when those patients were excluded.  
 
Sporadic patients 
Even though our sporadic cohort included only young-onset pituitary adenoma patients, a significant 
younger age at onset was still found within this young group in the AIPmut-positive simplex patients 
in comparison with the AIPmut-negative ones (median 16 [IQR 14.8-22.3] vs. 22 [IQR 16-26] years, 
P=0.0054, Supplemental Figure 4d), and there was a higher proportion of pediatric cases within the 
AIPmut-positive subgroup (58.8% vs. 35.9%, P=0.0085). Nevertheless, while the youngest age at 
onset in the AIPmut-positive simplex patients was nine years, 3% (11/369) of the AIPmut-negative 
patients had disease onset before the nine years of age, with a minimum age of three years.  
 
Clinical diagnoses 
GH excess patients accounted for 57.8% (524/906) of the total affected individuals in the entire 
cohort: 46.6% (234/502) of the familial and 71.8% (290/404) of the sporadic cases. Patients with GH 
excess, prolactinomas and NFPAs were present in both AIPmut-positive and negative subgroups, but 
Cushing’s disease, functioning gonadotropinomas and TSHomas were not found in patients bearing 
AIPmuts.  
 
Familial patients 
We classified the FIPA families as ‘homogeneous’, when all the affected individuals within the family 
had the same diagnosis (GH excess was considered as a single category), or ‘heterogeneous’, when 
different diagnoses were found in the same family (17). Around one half of the families in our cohort 
were homogeneous FIPA families (families with only one pituitary adenoma type) in both the 
AIPmut-positive (48.6%) and negative (52.5%) subgroups (Supplemental Table 4). The most common 
family type in both subgroups (according to the diagnostic categories found in the affected members) 
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was the pure GH excess family, but it was significantly more frequent within the AIPmut-positive 
FIPA families (P=0.0249). The most common diagnoses in AIPmut-positive and negative families 
were the different categories of GH excess; nevertheless, these cases were significantly more frequent 
in the AIPmut-positive subgroup, with at least one case of GH excess in 91.9% (34/37) of the AIPmut-
positive and in 53.1% (95/179) of the AIPmut-negative FIPA families (P<0.0001, Supplemental 
Figure 4e). There was a higher frequency of PRL co-secretion among the AIPmut-positive patients 
with acromegaly or gigantism, compared with the AIPmut-negative ones (P=0.0158, Supplemental 
Figure 4f). In the AIPmut-negative FIPA patients the most frequent diagnosis was acromegaly, in 
35.3% (137/389) of the patients, with prolactinoma in the second place of frequency (30.9%, 
120/389). In sharp contrast to AIPmut-positive families, where 31% (35/113) of the patients had 
gigantism, only 2.1% (8/389) of the AIPmut-negative FIPA patients had this diagnosis. 
 
Sporadic patients 
In the sporadic cohort, all the AIPmut-positive simplex patients harbored GH-secreting adenomas (vs. 
69.2% of the AIPmut-negative cases), as proven by the clinical diagnosis and immunohistochemistry 
(IHC) report. The predominance of GH excess cases in both groups could be due to a selection bias, 
as the previously reported association between AIPmuts and acromegaly/gigantism could have 
influenced the referral of these patients for the study.  
 
Histopathology 
Familial patients 
The IHC analysis of the operated pituitary adenomas confirmed the clinical/biochemical picture in the 
vast majority of the cases, reporting a predominance of somatotropinomas and mammosomatotroph 
adenomas in FIPA patients, more evident in the AIPmut-positive subgroup (P= 0.0304, Supplemental 
Figure 5a and b).  There was a unique case of a double adenoma (one tumor positive for GH and 
another one for PRL) and one unusual case of somatotroph hyperplasia in a patient with gigantism 
within the AIPmut-positive patients. None of the few AIPmut-positive clinically NFPA cases were 
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gonadotroph or null cell adenomas. In contrast, in the AIPmut-negative FIPA families, 48.3% of the 
NFPAs analyzed were reported as gonadotropinomas and 31% were null cell adenomas (based on 
negative immunostaining for GH, ACTH, PRL, TSH, LH and FSH). There was a similar prevalence 
of plurihormonal tumors in both subgroups (17.4% in the AIPmut-positive and 10.5% in the AIPmut-
negative families, P=0.2763). Seventy five percent of all the plurihormonal tumors in both subgroups 
had positive GH staining. There was a significant difference among the AIPmut-positive and negative 
FIPA patients involving the granulation pattern in GH positive adenomas. All the AIPmut-positive 
FIPA patients for whom this parameter was available (22/22) had sparsely granulated adenomas, 
while 43.8% (7/16) of the AIPmut-negative patients harbored densely granulated adenomas 
(P<0.0001, Supplemental Figure 5c); this difference could correspond to the response to the treatment 
with SSA, as suggested by previous reports (SR7). We found no difference in the proportion of 
patients with Ki-67 index t3% between the two subgroups (global 28.1%, P=1.0000).  
 
The presence of two different types of pituitary adenomas in the same gland is infrequent (2.3% of all 
the cases and 3.3% of the cases of Cushing’s disease) (SR8). Multiple pituitary adenomas have been 
previously described in a few cases of MEN1 and FIPA (not screened for AIPmuts) patients (SR9-13). 
Although somatotroph hyperplasia has been described before in the setting of AIPmuts (10;SR14), 
this finding does not seem to be particularly frequent, as in our cohort it was found only in one patient 
with acromegaly and PRL co-secretion.  
 
There was a marked predominance of sparsely granulated GH-secreting adenomas among the 
AIPmut-positive patients, compared with the AIPmut-negative ones. Patients with sparsely granulated 
tumors are usually younger at diagnosis than those with a densely granulated pattern (SR15;SR16), 
have increased invasiveness (SR7;SR15-17) and reduced response to the treatment with SSA 
(SR7;SR17), though the strength of these associations has been variable among different studies. The 
mechanism proposed for this effect in sporadic adenomas implies a reduced expression of the 
somatostatin receptor subtype 2 (SSTR2) (SR18;SR19). Since the expression of the SSTR2 and other 
somatostatin receptor subtypes is not reduced in somatotropinomas from AIPmut-positive patients, 
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other molecular mechanisms must be involved in the association of these mutations with decreased 
responsiveness to SSAs and a sparsely granulated pattern, such as ZAC1 activation (SR20;SR21) or 
an impaired inhibitory G protein subunit function in these tumors (SR22).  
 
Sporadic patients 
All the AIPmut-positive patients with available histopathology results (n=14) had GH positive 
pituitary adenomas by IHC, 28.6% of them (n=4) were mammosomatotroph adenomas (Supplemental 
Figure 5d). In contrast, the AIPmut-negative subgroup (n=89) included corticotropinomas (7.9%), null 
cell adenomas (3.4%), plurihormonal tumors (13.5%), prolactinomas (12.4%), somatotropinomas 
(32.6%), mammosomatotroph adenomas (29.2%), as well as a TSHoma (1.1%, Supplemental Figure 
5e). In the AIPmut-positive subgroup, one third (2/6) of the somatotroph adenomas with available 
cytokeratin staining had a densely granulated pattern and the rest were sparsely granulated. The 
distribution was similar in the AIPmut-negative subgroup, where 31.6% of the GH adenomas 
presented a densely granulated pattern (6/19) and 68.4% were sparsely granulated. Additionally, one 
AIPmut-negative patient had a somatotropinoma with a mixed granulation pattern.  
 
Pituitary adenoma size and extension  
Familial patients 
We compared size and extension of pituitary adenomas between AIPmut-positive and negative FIPA 
patients (Supplemental Figure 6), and for this purpose, the prospectively diagnosed AIPmut-positive 
patients were excluded from the analysis. Despite macroadenomas being predominant in both FIPA 
patient groups, the AIPmut-positive FIPA patients had larger tumors, demonstrated by a larger 
maximum diameter (P=0.0404, Supplemental Figure 6a) and a higher prevalence of macroadenomas 
(P<0.0001, Supplemental Figure 6b). The proportion of giant (maximum diameter ≥40mm) adenomas 
(6.3% in AIPmut-positive and 3% in AIPmut-negative patients) was not significantly different 
(P=0.1766). There was a higher frequency of extrasellar extension in AIPmut-positive FIPA patients 
with pituitary adenomas (P=0.004, Supplemental Figure 6c). Three of the AIPmut-negative, but none 
of the AIPmut-positive patients, harbored tumors with extensive invasion (defined as involvement of 
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intracranial areas beyond the perisellar region); two of them had somatotropinomas and the third one 
harbored a gonadotropinoma. None of the patients in our cohort had evidence of metastases to justify 
a diagnosis of pituitary carcinoma.  
 
Sporadic patients 
In the sporadic cohort, the maximum diameter of the tumors and the proportion of giant adenomas 
were similar between AIPmut-positive and negative sporadic cases (P=0.6965 and 0.7859, 
respectively). All the AIPmut-positive patients had macroadenomas (29/29) vs. 86.3% (283/328) of 
the AIPmut-negative subgroup, and the presence of extrasellar extension was more common in the 
former group (95% vs. 58.9%, P=0.0011).  
 
Apoplexy of the pituitary adenoma 
Excluding the prospectively diagnosed patients, symptomatic apoplexy of the pituitary adenoma 
occurred in 8.3% of the AIPmut-positive cases (9.1% of the familial cases, including three families 
with two cases per family, and 5.9% of the sporadic patients) and in only 1.3% of the patients in the 
AIPmut-negative subgroup (P<0.0001) and this difference remained significant when only the 
familial cases were analyzed (10.6% of the AIPmut-positive vs. 2.3% of the AIPmut-negative patients, 
P=0.0002, Supplemental Figure 6d). Eight (72.7%) of the AIPmut-positive patients with a history of 
pituitary apoplexy had a diagnosis of gigantism, and in three of them (27.2%) apoplexy was the 
manifestation that led to the diagnosis of pituitary disease (Supplemental Figure 6e). There were no 
significant differences in the age at onset/diagnosis or in the tumoral size between the AIPmut-
positive patients that developed pituitary apoplexy and those who did not have this complication. Out 
of ten AIPmut-negative pituitary adenoma patients with a history of apoplexy, six had NFPA, two had 
acromegaly, one had gigantism and the specific diagnosis was unknown in the last patient.  
 
The original description of multiple cases of pituitary adenoma apoplexy in AIPmut-positive patients 
(3) was later confirmed in other studies (4;12;25;SR14;SR23;SR24) as well as now in this larger 
cohort. Although the prevalence of 8.3% does not seem to be higher than the prevalence reported in 
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populations of unselected pituitary adenomas (7.9%) (SR25), in the latter study patients were older 
(mean age 60.5 years) and harbored NFPAs, while in our cohort the majority had gigantism and the 
rest, acromegaly or  prolactinoma, with a mean age at diagnosis of 23.4 years. Our three familial 
apoplexy families, together with a recently reported family with three apoplexy cases (SR24) provide 
support for the phenotype of young-onset, familial apoplexy in AIPmut-positive patients. To our 
knowledge, there are no previously known genetic causes of familial pituitary adenoma apoplexy, and 
this remains an uncommon finding. The mechanism why AIPmut-positive cases are more prone to 
apoplexy needs further study. 
 
GH excess patients 
With the purpose of analyzing a relatively homogeneous population of patients, we compared the 
main clinical features of the AIPmut-positive and negative GH excess patients from both cohorts, 
excluding the prospectively diagnosed patients. Similar to the whole study population, the GH excess 
AIPmut-positive patients had an earlier disease onset and diagnosis, had significantly more apoplexy 
cases (8.4 vs. 1.2%, P<0.0001) and a higher frequency of sparsely granulated tumors (91.7 vs. 57.1%, 
P=0.0073). In the AIPmut-positive subgroup there is a preponderance of males (60.7% [65/107]), in 
contrast with the gender distribution found in patients with all the diagnostic categories. PRL co-
secretion was more common in AIPmut-positive patients (14 vs. 5.9%, P=0.0046). There were no 
differences in tumor size, frequency of extrasellar extension, or giant tumors, though most of the 
tumors in both subgroups (89.5%) were macroadenomas. There was no significant difference in the 
number of therapeutic modalities employed between the two subgroups, but there were fewer patients 
cured or controlled in the AIPmut-negative subgroup (41/66 vs. 86/192, P=0.0151). Given that the 
AIPmut-positive patients had a significantly longer follow-up duration, we decided to evaluate the 
current status (i.e. effect of the therapies) only in patients with zero to five years of follow-up. In this 
subset of patients, there was no significant difference in the percentage of cured or controlled patients 
between the AIPmut-positive (57.1%) and the AIPmut-negative (41.7%) subgroups.  
 
Gigantism 
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This study included 120 patients with gigantism, 45 of them, (37.5%) were part of FIPA families and 
75 (62.5%) presented as sporadic patients. Overall, 46.7% (56/120) of the patients with gigantism 
were AIPmut-positive. Males were predominant among AIPmut-positive and negative patients (global 
67.5%), as expected for gigantism cases. Childhood-onset GH excess resulting in gigantism was more 
prevalent among the AIPmut-positive patients (48.3% [56/116]) than GH excess with no pathological 
body height, while the opposite pattern was observed in the AIPmut-negative subgroup (only 16.7% 
[64/408] had gigantism, P<0.0001). Sixty percent of the AIPmut-positive families had at least one 
patient with gigantism. The frequency of AIPmuts was much higher in the gigantism cases occurring 
in a familial setting (Supplemental Figure 7a), where 82.2% (37/45) of the patients were AIPmut-
positive, in comparison with the sporadic cohort, where AIPmut-positive patients accounted for only 
25.3% (19/75) of the patients (P<0.0001). Familial gigantism, defined as the occurrence of two or 
more gigantism cases due to pituitary adenoma in the same family, occurred only in AIPmut-positive 
FIPA families (9/37 families, 24.3%, Supplemental Figure 7b). Four of these families harbored the 
p.R304* AIPmut, and the AIPmuts g.4856_4857CG>AA, p.Q164*, p.269_H275dup, p.E24* and a 
whole gene deletion accounted for one family each. AIPmut-positive gigantism patients were taller 
than their AIPmut-negative counterparts if we considered the criterion of height >3SD over percentile 
50 but not when considering >2SD over midparental height (Supplemental Figure 7c and d). 
 
There was no difference in the age at diagnosis (global median 18 [IQR 15-23]) between the AIPmut-
positive and negative gigantism subgroups. Differences in the frequency of disease onset and 
diagnosis during the first decade of life did not reach statistical significance (onset: AIPmut-positive 
9.1% vs. AIPmut-negative 9.5%; diagnosis: 3.6% vs. 1.6%). There were no significant differences in 
the parameters of tumor size and extension either (maximum diameter, frequency of giant adenomas 
and extrasellar invasion). However, it is worth noting that the vast majority of the tumors in both 
subgroups were macroadenomas (global 91.5%), and most of them displayed extrasellar invasion 
(77.6%). A small percentage of the patients had PRL co-secretion at diagnosis (9.2% global, not 
significantly different between AIPmut-positive and negative patients). There were no significant 
differences in the number of treatments received or the frequency of controlled patients between the 
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two subgroups. Overall, 43.2% of all the patients with gigantism have currently active or only 
partially controlled disease. 
 
Extra-pituitary neoplasms in AIPmut-positive individuals 
To explore the possibility of a syndromic presentation, we looked for additional neoplasms in the 
affected and unaffected AIPmut-positive individuals (n=290). We found a total of ten cases of eight 
different extra-pituitary neoplasms (osteosarcoma, breast cancer, neuroendocrine tumor of the colon, 
gastrointestinal stromal tumor [GIST], glioma, meningioma, non-Hodgkin’s lymphoma and spinal 
ependymoma) in nine subjects (four patients and five unaffected AIPmut carriers, Supplemental Table 
5), accounting for 3.1% of the AIPmut-positive individuals studied. AIPmut-positive GH excess 
patients accounted for 44.4% (4/9) of the individuals with extra-pituitary neoplasms, while the rest 
were unaffected AIPmut-positive carriers. We note that the association of these tumors with AIPmuts 
could be coincidental.  
 
An increased risk of malignancy among unselected pituitary adenoma patients has been previously 
reported (SR26;SR27). We have also found neoplasms within the AIPmut-positive individuals with no 
pituitary adenomas, where hormonal excess, especially GH, does not play a role. Further analyses are 
needed to establish whether there is a possible association between AIPmuts and these neoplasms. 
Recently, germline AIPmuts have been associated with three cases of parathyroid adenomas (two 
middle aged women in the setting of non-familial, isolated hyperparathyroidism and a young male 
with acromegaly) (SR28;SR29). An MEN-1 like phenotype was an exclusion criterion in our study, 
therefore, it was not possible to assess this novel pathogenic association, and none of our patients or 
carriers developed hyperparathyroidism during the follow-up. 
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SUPPLEMENTAL FIGURES AND TABLES 
 
Supplemental Table 1. Definition of the clinical diagnostic categories used in our study. 
Diagnosis Criteria 
Cushing’s disease Evidence of ACTH-depending hypercortisolemia with proven pituitary adenoma, in accordance to the diagnostic protocol of each institution 
Clinically functioning FSH-secreting 
pituitary adenoma (FSHoma) 
Raised serum FSH levels for age and gender and evidence of gonadal stimulation in a patient 
with a pituitary adenoma 
GH excess 
Acromegaly Raised IGF-1 levels and unsuppressed GH during an oral glucose tolerance test (OGTT), with cut-offs according to the protocol of each institution 
Acromegaly/prolactinoma Diagnosis of acromegaly with concurrent hyperprolactinemia 
Mild acromegaly* 
Mild clinical features attributed to acromegaly, fulfilling the criterion of raised IGF-1 levels 
but not the lack of suppression of GH during an OGTT, or normal IGF-1 but lack of 
suppression of GH during an OGTT (16) 
Gigantism 
Any of the following categories in a patient with a pituitary adenoma: (i) abnormally high 
growth velocity in children or teenagers with abnormal IGF-1 and OGTT, (ii) height >3SD 
above the mean height for age, (iii)  >2SD over the calculated midparental height, using 
country-specific growth charts when possible 
Gigantism/prolactinoma Diagnosis of gigantism with concurrent hyperprolactinemia 
Clinically nonfunctioning pituitary 
adenoma (NFPA) 
Pituitary adenoma in the absence of clinical or biochemical evidence of pituitary 
hypersecretion 
Pituitary tumor Cases of pituitary tumor where the diagnosis could not be specified, due to unavailability of histopathological specimens, clinical and/or biochemical data 
Prolactinoma 
Hyperprolactinemia in the presence of a pituitary adenoma and unlikely to be purely due to a 
stalk effect, based on either histopathology results or the relation between PRL levels and 
tumor size 
Thyrotropinoma (TSHoma) Hyperthyrotropinemia in a patient with a pituitary adenoma, with clinical and/or biochemical hyperthyroidism and no other demonstrable causes of raised TSH 
* This category is important in our study, as we detected acromegaly via biochemical screening of AIPmut-positive carriers, often not 
presented (yet) clinically. 
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Supplemental Table 2. Other genes tested. 
 
 Familial cohort Sporadic cohort 
Combined, 
no. (%)  
AIPmut-
positive, 
no. (%) 
AIPmut-
negative, 
no. (%) 
Total 
familial,          
no. (%) 
AIPmut-
positive, 
no. (%) 
AIPmut-
negative, 
no. (%) 
Total 
sporadic,       
no. (%) 
BRCA1 1 (14.3) 2 (0.7) 3 (1) - - - 3 (0.8) 
BRCA2 1 (14.3) 2 (0.7) 3 (1) - - - 3 (0.8) 
CDKN1B - 20 (6.5) 20 (6.4) - 1 (2.4) 1 (2.4) 21 (5.9) 
GPR101 - - - - 8 (19) 8 (19) 8 (2.2) 
MAX - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
MEN1 3 (42.9) 51 (16.6) 54 (17.2) - 33 (78.6) 33 (78.6) 87 (24.4) 
PRKAR1A - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
RET - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHA - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHAF2 - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHB - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHC - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHD - 25 (8.1) 25 (8) - - - 25 (7) 
TMEM127 - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
TP53 2 (28.6) - 2 (0.6) - - - 2 (0.6) 
VHL - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
Total 7 307 314 0 42 42 712 
-, no individuals in this category. 
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Supplemental Table 3. AIP nonpathogenic mutations in the familial and sporadic cohorts. 
 
Variant (DNA level 
[protein level]) Variant type Pathogenic 
Location in 
protein 
Familial 
cohort* 
(N=19) 
Sporadic 
cohort* 
(N=37) 
Combined* 
(N=56) 
References/ 
SR‡ 
c.47G>A (p.R16H) Missense No N-terminus 0 2 2 (2;5;7)/ (SR31;39;54-58) 
c.132C>T (p.(=)) Synonymous No PPIase domain 0 3 3 (5)/(SR59) 
c.144C>T (p.(=)) Synonymous No PPIase domain 0 1 1 (SR53;59-61) 
c.516C>T (p.(=)) Synonymous No 
Between 
PPIase and 
TPR1 
domains 
8 13 21 (5;12)/(SR56;58;59;61-63) 
c.573C>T (p.(=)) Synonymous No TPR1 domain 0 0 0 This paper 
c.579G>T (p.(=)) Synonymous No TPR1 domain 1 0 1 This paper 
c.682A>C (p.K228Q) † Missense No 
Between 
TPR1 and 2 
domains 
2 16 18 (5)/(SR58;59;63) 
c.831C>T (p.(=)) Synonymous Unlikely TPR3 domain 1 0 1 This paper 
c.891C>A (p.(=)) Synonymous No TPR3 domain 0 2 2 (5)/(SR59) 
C.896C>T (p.A299V) Missense Unlikely TPR3 domain 5 0 5 (12)/(SR31) 
c.906G>A (p.(=)) Synonymous No C-terminal 
α-helix 2 0 2 (SR31;59) 
* Number of positive individuals for each mutation, considering the AIPmut-positive tested individuals, the obligate carriers and the 
predicted AIPmut patients. 
†There is a Q at this position in the AIP reference sequence, but we consider K as the wild type amino acid, due to its higher 
prevalence in the population screened so far (Stals K., unpublished data). 
PPIase, peptidylprolyl isomerase, TPR, tetratricopeptide repeat. 
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Supplemental Table 4. Classification of FIPA families by diagnoses 
  AIPmut-positive 
AIPmut-
negative Total 
Total families, no.: 37 179 216 
Diagnoses:    
Cushing's disease only, no. (%) - 3 (1.7) 3 (1.4) 
Cushing's disease + FSHoma, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease + NFPA, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease + NFPA + pituitary tumor, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease +  prolactinoma, no. (%) - 5 (2.8) 5 (2.3) 
FSHoma +  prolactinoma, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease+ GH excess, no. (%) - 7 (3.9) 7 (3.2) 
GH excess only, no. (%) 16 (43.2) 44 (24.6) 60 (27.8) 
GH excess + NFPA, no. (%) 8 (21.6) 12 (6.7) 20 (9.3) 
GH excess + NFPA + prolactinoma, no. (%) 1 (2.7%) 3 (1.7) 4 (1.9) 
GH excess + pituitary tumor, no. (%) - 5 (2.8) 5 (2.3) 
GH excess + pituitary tumor +  prolactinoma, no. (%) - 1 (0.6) 1 (0.5) 
GH excess +  prolactinoma, no. (%) 9 (24.3) 30 (16.8) 39 (18.1) 
NFPA only, no. (%) 2 (5.4) 17 (9.5) 19 (8.8) 
NFPA + pituitary tumor, no. (%) - 7 (3.9) 7 (3.2) 
NFPA +  prolactinoma, no. (%) 1 (2.7) 10 (5.6) 11 (5.1) 
Pituitary tumor +  prolactinoma, no. (%) - 1 (0.6) 1 (0.5) 
 Prolactinoma, no. (%) - 30 (16.8) 30 (13.9) 
* The category "GH excess" includes the following diagnoses: acromegaly, acromegaly/ prolactinoma, 
gigantism, gigantism/ prolactinoma and mild acromegaly. 
-, no families in this category. 
FSHoma, FSH secreting adenoma. NFPA, nonfunctioning pituitary adenoma.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
Supplemental Table 5. Extrapituitary neoplasms in AIPmut-positive individuals. 
 
Pituitary 
diagnosis Cohort Gender AIPmut Extrapituitary neoplasm 
Unaffected Familial Male c.910C>T (p.R304*) Osteosarcoma and neuroendocrine tumor of the colon † 
Unaffected Familial Female c.910C>T (p.R304*) Breast cancer† 
Unaffected Familial Female c.910C>T (p.R304*) Breast cancer† 
Acromegaly Familial Male c.805_825dup (p.F269_H275dup) GIST 
Acromegaly Familial Male c.241C>T (p.R81*) GIST* 
Unaffected Sporadic Male c.910C>T (p.R304*) Glioma 
Acromegaly Familial Female c.241C>T (p.R81*) Meningioma* 
Gigantism Familial Male c.74_81delins7 (p.L25Pfs*130) Non-Hodgkin’s lymphoma 
Unaffected Familial Female c.100-1025_279+357del (ex2del) (p.A34_K93del) Spinal ependymoma 
* Brother and sister. † Brother and 2 sisters.  
GIST, gastrointestinal stromal tumor. 
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Supplemental Figure 1. AIPmut types and frequency according to age at disease onset in the familial and 
sporadic cohorts (whole study population). a) Number of AIPmuts per mutation type, note the predominance of 
nonsense mutations. b) The probability of finding an AIPmut was higher when testing patients with disease onset 
during the second decade of life; c) in concordance, three quarters of all the AIPmut-positive patients had disease 
onset during the second and third decades of life.  
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Supplemental Figure 2.  AIPmuts detected in the study population and their position in the AIP gene. Shadowed areas indicate the protein domains codified by each 
region of the gene. Mutations producing a truncated or missing protein are shown at the bottom of the scheme, and nontruncating mutations are at the top. Even though we 
identified variants throughout the whole AIP gene, mutations tended to cluster in the genomic regions encoding the tetratricopeptide repeat (TPR) domains and the C-terminal 
α-helix of the protein. Furthermore, the mutations located at the N-terminal extreme and inside the peptidylprolyl isomerase (PPIase) domain were essentially truncating 
mutations, resulting in short and unstable proteins, lacking the TPR domains. As expected based on previous data (26;SR64), the commonest mutation in both cohorts was 
c.910C>T (p.R304*), found in 33.3% of the AIPmut patients and in 35.9% of all the AIPmut-positive individuals (affected plus unaffected carriers). There were no exclusive 
associations of specific AIPmuts with particular diagnoses. However, 77.4% of all the mutations (24/31) were found in cases of gigantism (with or without prolactin (PRL) 
co-secretion), being this the diagnosis with the highest number of associated AIPmuts. Furthermore, all the mutations were found in at least one patient with GH excess, 
supporting this diagnostic category as the most frequent AIPmut pathogenic association. Patients with diagnosis of NFPA harbored 29% (9/31) of the AIPmuts found in the 
study, and 22.6% of them (7/31) were detected in prolactinoma cases.  
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Supplemental Figure 3. Gender distribution in FIPA families and sporadic patients: a) Gender distribution was 
different between the AIPmut-positive and negative FIPA patients, due to a predominance of female patients within 
the AIPmut-negative families. b) This difference cannot be explained by a selection bias towards one specific gender, 
as there were similar numbers of males and females within the unaffected family members (excluding ‘not at risk’ 
individuals) of AIPmut-positive and negative FIPA families. c) The gender distribution was not significantly different 
between AIPmut-positive and negative patients, despite a slight prevalence of males in the AIPmut-positive subgroup. 
ns, not significant, **, P<0.01.  
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Supplemental Figure 4. Clinical features in FIPA families and sporadic patients: a) AIPmut-positive familial 
patients were younger at disease onset (P<0.0001), b) as most of them developed symptoms after the age of 10 and 
before the age of 40. c) There was a higher frequency of pediatric cases (n [total]=425) in the AIPmut-positive FIPA 
families, compared with the AIPmut-negative FIPA families. d) In the sporadic group, although all these patients were 
≤30 years at disease onset, AIPmut-positive individuals were significantly younger at disease onset than the AIPmut-
negative ones. e) GH excess and f) presence of GH and PRL co-secretion were significantly more frequent in AIPmut-
positive familial patients. *, P<0.05, **, P<0.01, ****, P<0.0001.  
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Supplemental Figure 5. Histopathological diagnoses in FIPA families and sporadic patients. The distribution of the IHC 
diagnoses was different between AIPmut-positive (a) and negative (b) familial patients, though GH positive tumors 
predominated in both subgroups. c) The analysis of the granulation pattern reported sparsely granulated tumors in all the 
AIPmut-positive and in 43.8% of the AIPmut-negative familial adenomas (P<0.0001). d) AIPmut simplex patients had GH 
positive adenomas (with or without positive PRL staining), while e) the AIPmut-negative sporadic patients had a variety of 
other tumor types. PRLoma, prolactinoma; GH/PRLoma, mammosomatotroph adenoma; ns, not significant; ****, P<0.0001. 
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Supplemental Figure 6. Tumor size and and pituitary apoplexy in FIPA families (excluding prospectively 
diagnosed AIPmut-positive patients): AIPmut-positive vs. AIPmut-negative patients. a) Pituitary adenomas were 
larger in AIPmut-positive familial patients (P=0.040), b) what was reflected in a higher frequency of macroadenomas 
(P=0.0001). c) In concordance with this, there was a higher frequency of extrasellar extension within AIPmut-positive 
patients (P=0.004). d) The occurrence of symptomatic apoplexy of the pituitary adenoma was significantly more 
common among the AIPmut-positive families, occurring in 10.6% of these patients (vs. 2.3% of the AIPmut-negative 
FIPA patients, (P=0.0002), including one phenocopy NFPA patient. e) Apoplexy was the first sign of pituitary disease 
in 4.3% of the AIPmut-positive familial patients, but only in 1% of the AIPmut-negative ones. * P<0.05, **, P<0.01, 
***, P<0.001, ****, P<0.0001.   
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Supplemental Figure 7. Characteristics of gigantism cases (familial n=45, sporadic n=75) and penetrance.  a) 
The great majority of the gigantism cases occurring in a familial setting were AIPmut-positive vs. only one quarter of 
those cases presenting sporadically (P<0.0001). b) In our study population, all the kindreds including more than one 
case of gigantism carried AIPmuts (this graph includes all the AIPmut-positive kindreds, FIPA and simplex patients, 
and the AIPmut-negative FIPA families). c) Considering only those patients fulfilling the criterion of height >3SD 
over percentile 50, AIPmut-positive patients were taller at diagnosis than the AIPmut-negative ones (P=0.0164); 
however, d) there was no significant difference in height when the comparison was done among patients fulfilling the 
criterion of >2SD over midparental height. e) In average, there were more affected individuals per family in the 
AIPmut-positive families (P<0.0001). ns, not significant, * P<0.05, ** P<0.01, ****, P<0.0001. 
